Suppr超能文献

评估 IMRT 和 VMAT 剂量准确性:在应用常用指标和行动水平时未能检测到系统误差的实际例子。

Evaluating IMRT and VMAT dose accuracy: practical examples of failure to detect systematic errors when applying a commonly used metric and action levels.

机构信息

Canis Lupus LLC, Merrimac, Wisconsin 53561.

出版信息

Med Phys. 2013 Nov;40(11):111722. doi: 10.1118/1.4826166.

Abstract

PURPOSE

This study (1) examines a variety of real-world cases where systematic errors were not detected by widely accepted methods for IMRT/VMAT dosimetric accuracy evaluation, and (2) drills-down to identify failure modes and their corresponding means for detection, diagnosis, and mitigation. The primary goal of detailing these case studies is to explore different, more sensitive methods and metrics that could be used more effectively for evaluating accuracy of dose algorithms, delivery systems, and QA devices.

METHODS

The authors present seven real-world case studies representing a variety of combinations of the treatment planning system (TPS), linac, delivery modality, and systematic error type. These case studies are typical to what might be used as part of an IMRT or VMAT commissioning test suite, varying in complexity. Each case study is analyzed according to TG-119 instructions for gamma passing rates and action levels for per-beam and/or composite plan dosimetric QA. Then, each case study is analyzed in-depth with advanced diagnostic methods (dose profile examination, EPID-based measurements, dose difference pattern analysis, 3D measurement-guided dose reconstruction, and dose grid inspection) and more sensitive metrics (2% local normalization/2 mm DTA and estimated DVH comparisons).

RESULTS

For these case studies, the conventional 3%/3 mm gamma passing rates exceeded 99% for IMRT per-beam analyses and ranged from 93.9% to 100% for composite plan dose analysis, well above the TG-119 action levels of 90% and 88%, respectively. However, all cases had systematic errors that were detected only by using advanced diagnostic techniques and more sensitive metrics. The systematic errors caused variable but noteworthy impact, including estimated target dose coverage loss of up to 5.5% and local dose deviations up to 31.5%. Types of errors included TPS model settings, algorithm limitations, and modeling and alignment of QA phantoms in the TPS. Most of the errors were correctable after detection and diagnosis, and the uncorrectable errors provided useful information about system limitations, which is another key element of system commissioning.

CONCLUSIONS

Many forms of relevant systematic errors can go undetected when the currently prevalent metrics for IMRT∕VMAT commissioning are used. If alternative methods and metrics are used instead of (or in addition to) the conventional metrics, these errors are more likely to be detected, and only once they are detected can they be properly diagnosed and rooted out of the system. Removing systematic errors should be a goal not only of commissioning by the end users but also product validation by the manufacturers. For any systematic errors that cannot be removed, detecting and quantifying them is important as it will help the physicist understand the limits of the system and work with the manufacturer on improvements. In summary, IMRT and VMAT commissioning, along with product validation, would benefit from the retirement of the 3%/3 mm passing rates as a primary metric of performance, and the adoption instead of tighter tolerances, more diligent diagnostics, and more thorough analysis.

摘要

目的

本研究(1)研究了多种在广泛接受的 IMRT/VMAT 剂量准确性评估方法中未检测到的系统误差的实际案例,(2)深入研究了识别失效模式及其相应检测、诊断和缓解方法。详细研究这些案例的主要目的是探索更敏感的方法和指标,以便更有效地评估剂量算法、输送系统和 QA 设备的准确性。

方法

作者提出了七个实际案例研究,代表了治疗计划系统 (TPS)、直线加速器、输送方式和系统误差类型的各种组合。这些案例研究是 IMRT 或 VMAT 调试测试套件中可能使用的一部分,其复杂性各不相同。每个案例研究都根据 TG-119 关于伽马通过率和单束和/或综合计划剂量 QA 的行动水平进行分析。然后,使用先进的诊断方法(剂量分布检查、基于 EPID 的测量、剂量差异模式分析、3D 测量引导的剂量重建和剂量网格检查)和更敏感的指标(2%局部归一化/2 毫米 DTA 和估计的 DVH 比较)对每个案例研究进行深入分析。

结果

对于这些案例研究,传统的 3%/3 毫米伽马通过率超过了 IMRT 单束分析的 99%,综合计划剂量分析的范围为 93.9%至 100%,均远高于 TG-119 的 90%和 88%的行动水平。然而,所有案例都存在系统误差,只有使用先进的诊断技术和更敏感的指标才能检测到这些误差。系统误差导致了不同但值得注意的影响,包括目标剂量覆盖率损失高达 5.5%和局部剂量偏差高达 31.5%。误差类型包括 TPS 模型设置、算法限制以及 TPS 中 QA 体模的建模和对准。大多数误差在检测和诊断后是可以纠正的,无法纠正的误差提供了有关系统限制的有用信息,这是系统调试的另一个关键要素。

结论

当使用当前流行的 IMRT∕VMAT 调试指标时,许多相关的系统误差可能会被忽略。如果使用替代方法和指标代替(或除了)传统指标,这些误差更有可能被检测到,只有在检测到后,才能对其进行正确诊断并从系统中排除。消除系统误差不仅应该是最终用户调试的目标,也是制造商产品验证的目标。对于任何无法消除的系统误差,检测和量化它们都很重要,因为这将帮助物理学家了解系统的限制,并与制造商合作改进。总之,IMRT 和 VMAT 调试以及产品验证将受益于淘汰 3%/3 毫米通过率作为主要性能指标,并采用更严格的公差、更勤奋的诊断和更彻底的分析。

相似文献

引用本文的文献

5
MR-linac: role of artificial intelligence and automation.磁共振直线加速器:人工智能与自动化的作用
Strahlenther Onkol. 2025 Mar;201(3):298-305. doi: 10.1007/s00066-024-02358-9. Epub 2025 Jan 22.

本文引用的文献

8
[Electronic portal image device dosimetry for volumetric modulated arc therapy].
Nihon Hoshasen Gijutsu Gakkai Zasshi. 2013 Jan;69(1):11-8. doi: 10.6009/jjrt.2013_jsrt_69.1.11.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验